| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Neumora Therapeutics, Inc.$1.68
+0.06 (+3.64%)
D 38Pipeline Score Undervalued Biotech · Commercial
Market Cap
342.78 M
EPS
-1.33
P/E Ratio
-
Value Trade
1.12 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
38.60 M
Operating CF
-46.40 M
Total Assets
153.88 M
Total Liabilities
83.20 M
Equity
70.68 M
D/E Ratio
12,345
-4.64 %
Week
-23.55 %
1 Month
-46.84 %
3 Month
-21.28 %
6 Month
-88.79 %
5 Year
-88.79 %
All Time
Cash Data
Cash Position
147.07 M
Monthly Burn
15.47 M
Runway
7.6 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.02 M
52 Week Range
0.66 - 3.65
% held by Insiders
57.62 %
% held by Institutions
25.37 %
Enterprise Value
249.08 M
Total Shares
167.25 M
Short %
9.7 %
Float Shares
68.91 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neumora Therapeutics, Inc.
140Total events
9Upcoming
45Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 9
Event history 131
Jun 15, 2026
▼Primary Endpoint MissedNavacaprantDiscontinuedClinical Data
KOASTAL-2 did not achieve statistical significance on primary endpoint
major depressive disordersource ↗
Jun 15, 2026
▼Program DiscontinuationNavacaprantDiscontinuedCorporate
Company discontinuing development of navacaprant
major depressive disordersource ↗
Jun 2026
Jun 2026
Jun 2026
May 19, 2026
◆Oral PresentationPresentation
Fireside chat at 2026 RBC Capital Markets Global Healthcare Conference
Apr 13, 2026
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
Drug Pipeline Intelligence
D38
Pipeline Score $405M
Pipeline ValueUndervalued
Valuation Signal2
Drugs Scored3.9x
rNPV / MCap Top 53%
Micro Cap (rank 429 of 911)
Percentile RankNeumora Therapeutics, Inc. faces pipeline headwinds (38/100), with $1.4B risk-adjusted pipeline value, led by NMRA-335140 in Major Depressive Disorder (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NMRA-335140 Small molecule | Major Depressive Disorder | Phase 3 | NCT06029439 | 49% | $1.3B | ACTIVE NOT_RECRUITING | 2,251 | AVERAGE | D (32) | Jun 1, 2027 | LOW_RISK | MEDIUM Jun 9, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
navacaprant | major depressive disorder | Phase 3 | 2026-06-15 | KOASTAL 2 enrollment: 430; KOASTAL 3 enrollment: 422; patients analyzed: 426 Read More | Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update Read More | |
navacaprant | major depressive disorder | Phase 3 | 2026-06-15 | KOASTAL 2 enrollment: 430; KOASTAL 3 enrollment: 422; patients analyzed: 426 Read More | Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update Read More | |
navacaprant | major depressive disorder | Phase 3 | 2026-06-15 | KOASTAL 2 enrollment: 430; KOASTAL 3 enrollment: 422; patients analyzed: 426 Read More | Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NMRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NMRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NMRA▼ -48.6%on this news
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies for navacaprant in major depressive disorder failed to meet primary endpoints, leading to the discontinuation of its development. Despite this setback, the company remains optimistic about its other programs, including NMRA-511 for Alzheimer's agitation and NMRA-898 for schizophrenia. Neumora plans to reduce its workforce by 35% to achieve cost savings while maintaining a cash runway into Q3 2027.
Read more →NMRA▼ -6.3%on this news
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
Neumora Therapeutics will participate in the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company aims to redefine neuroscience drug development with its innovative therapeutic pipeline. A live webcast of the event will be available on their website, with a replay accessible for 30 days post-event.
Read more →NMRA▼ -16.7%on this news
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics reported its first quarter 2026 financial results, highlighting significant progress in its clinical trials, including the KOASTAL-2 and -3 studies for navacaprant. The company has a strong cash position of $147.1 million, expected to support operations into Q3 2027. Data from ongoing studies for NMRA-511 and NMRA-898 is anticipated in the second half of 2026.
Read more →NMRA▲ +6%on this news
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
Neumora Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The event will feature a fireside chat at 10:15 a.m. ET, with a live webcast available on their website. Neumora aims to redefine neuroscience drug development with novel therapies.
Read more →NMRA▼ -17.2%on this news
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Neumora Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position and advancements in its clinical pipeline. The company announced promising data for NMRA-511 in Alzheimer's disease agitation and confirmed full enrollment in the KOASTAL-2 and -3 studies. Despite a net loss, Neumora remains on track for significant milestones in 2026.
Read more →NMRANeumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Read more →NMRAFebruary 2026 Guggenheim Emerging Outlook: Biotech Summit Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” &#x
Neumora Therapeutics, Inc. presented forward-looking statements regarding their developments in neuroscience drug development, especially focusing on NMRA-511 for Alzheimer's disease agitation. The data from Phase 1b trials highlighted NMRA-511's superior efficacy compared to its placebo in reducing agitation symptoms, particularly among patients with elevated anxiety. However, there are inherent risks associated with drug development, including reliance on third parties and potential side effects that need further assessment.
Read more →NMRANeumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Neumora Therapeutics, a clinical-stage biopharmaceutical company, will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The event will feature a fireside chat, which will be available via live webcast on the company's website. Neumora aims to redefine neuroscience drug development with its innovative therapeutic pipeline.
Read more →NMRAImportant Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including statements r
Neumora Therapeutics is focused on advancing neuroscience by developing novel therapies aimed at improving treatment outcomes for various neurological conditions. The company is preparing for key clinical trials and anticipates several significant milestones in 2026, while maintaining a strong financial position. However, inherent risks in clinical development and reliance on external partners remain. Future results are uncertain and contingent on several factors outlined in their disclosures.
Read more →NMRANeumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
Neumora Therapeutics announced its 2026 pipeline strategy, highlighting several key clinical milestones, including the joint readout of KOASTAL-2 and KOASTAL-3 and the initiation of the NMRA-215 program. The company reported positive Phase 1b results for NMRA-511, indicating a meaningful effect on Alzheimer's agitation. Neumora is well-positioned financially to support its operations through 2027.
Read more →NMRANeumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
Neumora Therapeutics announced positive results from its Phase 1b study of NMRA-511 for Alzheimer's disease agitation. The study demonstrated a significant reduction in agitation symptoms and a favorable safety profile. Neumora plans to advance NMRA-511's development, including exploring higher doses in future cohorts.
Read more →NMRANeumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Neumora Therapeutics reported strong third quarter results, highlighting class-leading data from NMRA-215, an oral NLRP3 inhibitor, and plans to initiate a Phase 1 study in early 2026. The company is also advancing Phase 1 studies for two positive allosteric modulators and expects to report data from a Phase 1b study in Alzheimer's agitation by year-end. Neumora's financial position remains robust with $171.5 million in cash, supporting operations into 2027.
Read more →NMRANeumora Therapeutics to Participate in Upcoming Conferences in November
Neumora Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences scheduled for November. The company aims to showcase its innovative pipeline, which includes seven programs targeting novel mechanisms for treating prevalent diseases. Live webcasts of the events will be accessible on their website, with replays available for 30 days.
Read more →NMRANeumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Neumora Therapeutics has initiated a Phase 1 clinical study for NMRA-898, a positive allosteric modulator targeting the M4 muscarinic receptor. This follows the earlier initiation of a similar study for NMRA-861. Both compounds aim to improve treatment options for schizophrenia, potentially offering better safety profiles than existing therapies. A comprehensive update on the M4 franchise is expected by mid-2026.
Read more →NMRANeumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Neumora Therapeutics announced promising preclinical results for NMRA-215, a novel oral NLRP3 inhibitor, showing up to 26% weight loss in combination with semaglutide. The drug demonstrated significant efficacy as a monotherapy as well. Neumora plans to begin Phase 1 clinical studies in the first quarter of 2026, reinforcing its commitment to innovative obesity treatments.
Read more →NMRANeumora Therapeutics to Host Virtual R&D Day on October 27
Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, to present its innovative pipeline. The event will highlight NMRA-215, a potent NLRP3 inhibitor, and discuss expectations for NMRA-511's Phase 1b data. Neumora aims to redefine neuroscience drug development with its seven programs targeting significant medical challenges.
Read more →NMRANeumora Therapeutics to Participate in Upcoming Conferences in September
Neumora Therapeutics to Participate in Upcoming Conferences in September
Read more →NMRANeumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM)
Neumora Therapeutics has reported its financial results for Q2 2025, highlighting its active pipeline and business updates. The company initiated a Phase 1 study for NMRA-861, a positive allosteric modulator with potential in schizophrenia, with data expected in early 2026. Additionally, NMRA-215 has been prioritized as the lead indication for obesity, aiming to address unmet needs in weight loss therapies. Neumora also anticipates several critical clinical data readouts over the next year and maintains a strong cash position of $217.6 million.
Read more →NMRANeumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Read more →NMRA▲ +13.1%on this news· ran to +41% by day 3
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
Read more →NMRANeumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for
Neumora Therapeutics reported its financial results for Q1 2025 and provided a business update. The company is on track to report topline data for NMRA-511 in Alzheimer's disease agitation by late 2025. Neumora also resumed enrollment for its KOASTAL studies and announced its progress toward bringing an M4 positive allosteric modulator into the clinic by mid-2025. Additionally, it secured a $125 million venture debt facility, enhancing its financial stability and extending its operational runway into 2027.
Read more →NMRANeumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Read more →NMRANeumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRA
Neumora Therapeutics, Inc. is facing a class action lawsuit initiated by Levi & Korsinsky, LLP, on behalf of investors affected by alleged securities fraud. The lawsuit claims that Neumora made misleading statements and did not adequately disclose details related to its Phase Two trial for Navacaprant, particularly regarding the inclusion criteria and data reliability. Affected investors have until April 7, 2025, to seek appointment as lead plaintiffs.
Read more →NMRANeumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.
Neumora Therapeutics, Inc. is facing a class action lawsuit led by the Portnoy Law Firm, informing investors of their legal rights and options to recover losses from investments made since September 15, 2023. The lawsuit claims that Neumora misled investors by modifying key trial criteria and failing to disclose critical information regarding their developmental programs. The deadline for investors to file a lead plaintiff motion is April 7, 2025. The firm is offering complimentary evaluations to discuss potential claims.
Read more →NMRA▼ -8.7%on this news· ran to -26% by day 3shared move
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Neumora Therapeutics, Inc. Investors of Upcoming Deadline
Neumora Therapeutics, Inc. is facing a securities fraud class action lawsuit filed in the U.S. District Court for the Southern District of New York. The lawsuit alleges that the company and its senior officers made misrepresentations concerning known risks about their drug candidate, Navacaprant, during its initial public offering on September 15, 2023. A reminder has been issued for affected investors regarding a deadline to participate as lead plaintiffs, emphasizing the legal risks involved for shareholders. Those invested since the IPO may have incurred financial losses, raising concerns over the company's disclosures.
Read more →NMRANeumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 7, 2025 Deadline to file Lead Plaintiff Motion
Neumora Therapeutics, Inc. faces a class action lawsuit from investors who claim that the company made false statements regarding its Phase Two trial of Navacaprant. The law firm, Portnoy Law Firm, is encouraging affected investors to file a lead plaintiff motion by April 7, 2025. Allegations include the manipulation of trial data and inclusion criteria to falsely demonstrate the drug's efficacy in treating Major Depressive Disorder. Additionally, deficiencies in the trial's data, particularly related to patient demographics, have raised serious concerns.
Read more →NMRANeumora Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRA
Neumora Therapeutics, Inc. is facing a class action lawsuit initiated by The Gross Law Firm, with a lead plaintiff deadline set for April 7, 2025. The allegations state that the company misled investors regarding the Phase Two trials of their flagship therapeutic candidate, Navacaprant, especially regarding the inclusion criteria for trial participants. Critics contend the trial data was insufficient, raising concerns about the validity of subsequent studies. Shareholders are encouraged to register for potential participation in the class action to protect their interests.
Read more →NMRA▼ -5%on this newsshared move
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion
Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the efficacy of its therapeutic candidate, Navacaprant. The lawsuit claims that the company altered clinical trial parameters and lacked adequate data in its studies. Investors are urged to file a lead plaintiff motion by April 7, 2025, to recover losses incurred during the class period. The Portnoy Law Firm is facilitating this process, offering complimentary case evaluations to affected investors.
Read more →NMRANeumora Therapeutics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit
Neumora Therapeutics, Inc. is facing a securities fraud class action lawsuit filed in the Southern District of New York. The lawsuit highlights allegations of misleading statements and insufficient data in the company's Phase Two trials connected to its initial public offering. Investors are encouraged to participate in the lawsuit by acting as lead plaintiffs by the deadline of April 7, 2025. The lawsuit raises significant concerns regarding the integrity of Neumora's clinical trial processes and investor communication.
Read more →NMRANeumora Therapeutics to Present at Leerink Global Healthcare Conference
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
Read more →NMRA▼ -9.9%on this newsshared move
Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in
Neumora Therapeutics has reported its financial results for Q4 and full year 2024, revealing a robust cash position of $307.6 million which is expected to sustain operations through mid-2026. The company has optimized its ongoing KOASTAL-2 and -3 studies based on insights from KOASTAL-1, with topline data anticipated in 2026. Additionally, topline results from the NMRA-511 study in Alzheimer's agitation are expected by the end of 2025, signaling ongoing progress in their diverse neuroscience pipeline despite a net loss reported for the year.
Read more →NMRA▼ -9.9%on this newsshared move
Neumora Therapeutics, Inc. (NMRA) Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Neumora Therapeutics is facing a securities class action lawsuit related to its initial public offering in September 2023. The lawsuit, filed in the Southern District of New York, claims that the company made materially false statements regarding its clinical trial data, particularly concerning its Phase Two Trials for the treatment of major depressive disorder. The lead plaintiff deadline for investors wishing to join the class action is set for April 7, 2025. The allegations highlight concerns regarding the validity of clinical trial data and company disclosures to investors.
Read more →NMRA▲ +5.3%on this newsshared move
Neumora Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – NMRA
Levi & Korsinsky, LLP has filed a class action lawsuit against Neumora Therapeutics, Inc. for alleged securities law violations. The complaint claims that the company made false statements regarding its Phase Two clinical trial for Navacaprant and manipulated trial criteria to present favorable results. Investors who suffered losses between September 15, 2023, and the present may join the lawsuit, which allows for potential recovery without financial risks. Interested parties must act before the April 7, 2025 deadline to be considered for lead plaintiff status.
Read more →NMRANeumora Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NMRA
Robbins LLP has filed a class action on behalf of investors against Neumora Therapeutics, alleging misleading information in the Offering Documents related to its IPO. The case concerns the company’s leading drug candidate, Navacaprant, which reportedly did not meet the expected efficacy benchmarks during clinical trials, specifically the KOASTAL-1 study. Following the negative results, Neumora's stock price sharply dropped from its IPO price of $17 to $1.91. Shareholders are urged to file as lead plaintiffs by April 7, 2025, to participate in the lawsuit.
Read more →NMRANeumora Therapeutics Announces Leadership Transition Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president B
Neumora Therapeutics has announced a significant leadership transition, with Paul L. Berns stepping up as CEO and chairman, while Joshua Pinto, Ph.D. will become president. The company boasts a robust pipeline of seven clinical and preclinical programs targeting brain diseases. Neumora expects to deliver important clinical data readouts in 2025, which may enhance their position in the market. The change in leadership comes alongside the departure of Henry Gosebruch, raising some uncertainty. Overall, the company aims to address unmet needs in brain disease treatments and maximize shareholder value.
Read more →NMRANeumora Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc.
A securities class action lawsuit has been initiated against Neumora Therapeutics, Inc. in the Southern District of New York, with claims of misrepresentation during its IPO. The lawsuit alleges that the company failed to adequately disclose risks associated with its Phase Three program, including amendments to trial criteria and insufficient data from earlier trials. Following this, Neumora's stock has significantly devalued, dropping from $17 at IPO to $1.67. Investors who suffered losses are encouraged to join the lawsuit by the deadline of April 7, 2025.
Read more →NMRANeumora Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NMRA
Neumora Therapeutics, Inc. is currently being sued for securities law violations, specifically concerning allegations of securities fraud related to its Phase Three Program. The lawsuit includes claims that the company made false statements and failed to adequately disclose information during its Phase Two trials, which may have impacted investor decisions. Affected investors are encouraged to contact Levi & Korsinsky for participation in the class action, with a deadline to act set for April 7, 2025. The firm highlights its experience in successfully representing aggrieved shareholders in securities litigation.
Read more →NMRA▼ -6.2%on this newsshared move
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: Investors With Large Losses in Neumora Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has announced a class action lawsuit against Neumora Therapeutics, Inc. for alleged misrepresentations made during its IPO. The lawsuit claims that the company failed to disclose known risks concerning its flagship drug candidate, Navacaprant, during the initial public offering in September 2023. Investors impacted by these misrepresentations are encouraged to take action by the April 7, 2025, deadline to file as lead plaintiffs. The law firm emphasizes that they operate on a contingency fee basis, allowing shareholders to pursue claims without upfront costs.
Read more →NMRA▼ -81.4%on this news
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms a
Neumora Therapeutics announced the results of its KOASTAL-1 study of navacaprant, which did not show statistically significant improvement in reducing depressive symptoms compared to placebo. While there was an efficacy signal in female participants, overall results were disappointing, and further analysis will be conducted. Navacaprant was generally well tolerated, and Neumora has a robust financial foundation to continue its developmental pipeline. The public will receive further updates during the upcoming J.P. Morgan Healthcare Conference.
Read more →NMRA▼ -17.1%on this news
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data
Neumora Therapeutics reported its financial results for Q3 2024 and provided updates on its clinical pipeline, which includes studies of navacaprant for major depressive disorder (MDD) and NMRA-511 for Alzheimer's disease agitation. The company expects to release topline data from its pivotal KOASTAL studies at the end of 2024 and the first half of 2025, respectively. Neumora maintains a strong cash position expected to support its operations through mid-2026. However, the company reported a net loss of $72.5 million for the quarter, highlighting the financial strains amid ongoing clinical development efforts.
Read more →NMRANeumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Read more →NMRANeumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Neumora Therapeutics Inc. will host a roundtable discussion on September 12, 2024, focusing on the role of kappa opioid receptor antagonists in neuropsychiatry. The event will feature expert opinions and updates on Neumora's clinical development of navacaprant for major depressive disorder and bipolar depression. Enthusiasm for the drug is noted among medical experts, with plans for data reporting from ongoing clinical studies in the forthcoming quarters.
Read more →NMRANeumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in M
Neumora Therapeutics reported its financial results for Q2 2024, highlighting a robust pipeline targeting neuropsychiatric disorders. The company is expecting Phase 3 results from the KOASTAL-1 study of navacaprant for MDD in Q4 2024, alongside advancements in studies for bipolar depression and Alzheimer's disease agitation. Neumora's financial position remains strong with $371.6 million in cash, expected to support operations into 2026. Despite reporting a net loss, the company is confident in its innovative approaches and the potential for favorable outcomes from its clinical trials.
Read more →NMRANeumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation
Read more →NMRA▲ +6.9%on this news
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Read more →NMRANeumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of
Neumora Therapeutics reported its first-quarter 2024 financial results and an update on its clinical programs. The company is on track to share topline Phase 3 data from the KOASTAL-1 study focusing on navacaprant for major depressive disorder in Q4 2024. Neumora also plans to initiate multiple clinical studies in 2024, including a Phase 2 trial for bipolar depression and a Phase 1b study for Alzheimer's disease agitation. However, the firm faced a net loss of $53.7 million in the quarter and a clinical hold on one of its programs.
Read more →NMRANeumora Therapeutics to Participate in Upcoming Conferences in May
Neumora Therapeutics, Inc. (Ticker: NMRA) has announced its participation in two investor conferences in May 2024, demonstrating its commitment to engage with the investment community. The BofA Securities Healthcare Conference will take place on May 14 in Las Vegas, while the RBC Capital Markets Global Healthcare Conference is scheduled for May 15 in New York. Neumora's therapeutic pipeline includes seven clinical and preclinical neuroscience programs aimed at addressing various neuropsychiatric and neurodegenerative disorders, signifying a robust approach toward treating brain diseases.
Read more →NMRA▼ -17.5%on this news
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Read more →NMRA▼ -14.6%on this news
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
Neumora Therapeutics, Inc. will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on March 20, 2024. This engagement highlights the company's commitment to redefining neuroscience drug development through innovative therapeutic approaches. Neumora is focused on addressing the global brain disease crisis with a pipeline that includes several neuroscience programs targeting underserved disorders. The event will be accessible via a live webcast on the company's website.
Read more →NMRANeumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of
Neumora Therapeutics reported its financial results for Q4 and the full year 2023, highlighting a strong cash position of $463.8 million. The company remains on track to provide topline data from the Phase 3 KOASTAL-1 study involving its KOR antagonist, navacaprant, for major depressive disorder (MDD) in late 2024. Additionally, Neumora is advancing its NMRA-266 program, with Phase 1 data expected in mid-2024 and is preparing for several key clinical trials. Despite commendable progress, the company reported a significant net loss, reflecting its ongoing investment in pipeline development.
Read more →NMRA▲ +9.9%on this news
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
Neumora Therapeutics has appointed Kaya Pai Panandiker as Chief Commercial Officer, who brings over 20 years of experience in commercializing treatments for major psychiatric disorders. With a history of successful product launches at companies like Lundbeck and Cerevel Therapeutics, her expertise is expected to advance Neumora's commercial strategy. The company is focused on developing therapies for schizophrenia, major depressive disorder, and several neurodegenerative diseases. This strategic appointment aims to transform treatment standards for patients with brain diseases.
Read more →NMRANeumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Read more →NMRAJ.P. Morgan Healthcare Conference January 2024 Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the "Company," "we," "us," or "our") within the meaning of the
Neumora Therapeutics, Inc. presented forward-looking statements at the J.P. Morgan Healthcare Conference, highlighting its intention to advance novel therapies for brain diseases. The company has raised $650 million in private capital and initiated multiple clinical trials for its compounds, including Navacaprant, which shows potential efficacy in treating major depressive disorder. With a pipeline addressing significant patient populations, Neumora aspires to redefine neuroscience drug development. However, the company acknowledges the inherent risks associated with clinical trials and regulatory approvals.
Read more →NMRANeumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
Neumora Therapeutics has announced the appointment of Jason Duncan as its new Chief Legal Officer. Duncan, who has over 20 years of experience in the life sciences sector, will join Neumora's Executive Team and oversee legal and compliance functions. He previously held key positions at Albireo Pharma, where he helped grow the company into a commercial organization. Neumora is dedicated to innovating neuroscience drug development and has a robust pipeline of therapies aimed at treating brain diseases.
Read more →NMRANeumora Therapeutics Announces IND Clearance and Initiation of Phase 1 Study of NMRA-266
Neumora Therapeutics Announces IND Clearance and Initiation of Phase 1 Study of NMRA-266
Read more →NMRANeumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
Neumora Therapeutics has announced the clearance of an Investigational New Drug (IND) application for NMRA-266, which is a selective positive allosteric modulator targeting the M4 muscarinic receptor. The company has initiated a Phase 1 clinical study to evaluate NMRA-266's safety and efficacy in healthy adult participants. With its favorable pharmacologic profile observed during pre-clinical trials, NMRA-266 aims to offer a novel treatment approach for schizophrenia and other neuropsychiatric disorders, addressing significant unmet medical needs in this area.
Read more →NMRANeumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression t
Neumora Therapeutics reported its financial results for Q3 2023, highlighting progress in its Phase 3 KOASTAL program for navacaprant, which targets major depressive disorder. The company plans to initiate a Phase 2 trial for bipolar depression in the first half of 2024. Despite a net loss of $53.0 million during the quarter, Neumora maintains a robust financial position with $519.5 million in cash, projected to support operations through 2026. The report also addresses the advancement of its other clinical and preclinical programs aimed at neuropsychiatric disorders.
Read more →NMRA▼ -6.4%on this news· ran to -17% by day 3
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Neumora Therapeutics has appointed Dr. Robert Lenz as the new executive vice president and head of research and development. Dr. Lenz, who has over 20 years of experience in neuroscience drug development, will report to CEO Henry Gosebruch. His prior roles include leading global development at Amgen, where he oversaw over 130 clinical studies. Neumora aims to redefine neuroscience drug development and advance its pipeline of therapies targeting various brain disorders.
Read more →NMRANeumora Therapeutics Announces Pricing of Initial Public Offering
Neumora Therapeutics Announces Pricing of Initial Public Offering
Read more →NMRANeumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer
Neumora Therapeutics has appointed Henry Gosebruch as President and CEO, succeeding co-founder Paul L. Berns, who will become Executive Chairman. Gosebruch brings over 25 years of industry experience, particularly from AbbVie, where he led corporate strategy. Neumora aims to redefine neuroscience drug development and tackle the global brain disease crisis with its innovative pipeline.
Read more →NMRANeumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder
Neumora Therapeutics has announced the initiation of the KOASTAL Program, a Phase 3 clinical trial for navacaprant (NMRA-140) targeting major depressive disorder (MDD). Following a successful Phase 2 study and a positive FDA meeting, the program aims to evaluate the drug's efficacy and safety. The pivotal studies are expected to support a New Drug Application by 2025.
Read more →NMRANeumora Therapeutics Announces $112 Million Series B Financing
Neumora Therapeutics Announces $112 Million Series B Financing
Read more →NMRANeumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
Read more →Competitive Position
How NMRA ranks across every disease it competes inCompetitive Position is a premium feature
See how NMRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial